Aktieanalys

Cantargia Q1 2024: Notable Cost Reductions - Redeye

{newsItem.title}

Redeye Publicerad: 22 May 14:06

Redeye comments on Cantargia's Q1 report. The main thing that stands out is the great Q/Q cost reduction. There has also been developments in inflammatory diseases relevant for CAN10.

Länk till analysen i sin helhet: https://www.redeye.se/research/1009444/cantargia-q1-2024-notable-cost-reductions?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt